Isolated Nodal Retroperitoneal Sporadic Lymphangioleiomyomatosis

Authors

  • Bárbara Soeiro Serviço de Medicina, Unidade Local de Saúde de Matosinhos, Hospital Pedro Hispano, Matosinhos, Portugal https://orcid.org/0000-0001-9545-6534
  • João Correia-Pinto Serviço de Anatomia Patológica, Unidade Local de Saúde de Matosinhos, Hospital Pedro Hispano, Matosinhos, Portugal https://orcid.org/0000-0003-1993-1705
  • Alexandre Vasconcelos Serviço de Medicina, Unidade Local de Saúde de Matosinhos, Hospital Pedro Hispano, Matosinhos, Portugal
  • Matilde Salgado Serviço de Oncologia, Unidade Local de Saúde de Matosinhos, Hospital Pedro Hispano, Matosinhos, Portugal

DOI:

https://doi.org/10.24950/CC/93/20/4/2020

Keywords:

Lymphangioleiomyomatosis, Lymph Nodes, Menopause

Abstract

Lymphangioleiomyomatosis is a rare disease (1/1 000 000) with multisystemic involvement, most commonly presenting with cystic lung disease. Reports of isolated nodal lymphangioleiomyomatosis rare. Its treatment and prognosis are not well established. We describe a 48-year-old female patient presenting with ureter compression by an extensive retroperitoneal mass. Biopsy showed nodal lymphangioleiomiomatosis. A partial surgical resection of the lesions was performed. She is under yearly thoraco-abdomino-pelvic computed tomography control, last performed 3 years after diagnosis, with no lung involvement or new abdominal lesions. She evolved to menopause after 6 months. Some case series suggest that isolated nodal lymphangioleiomyomatosis may precede lung involvement by one to two years, having size as a risk factor (>10 mm). Relative stabilization of the disease course in postmenopausal women is described. This case reports an atypical evolution, with two >10mm diameter lesion, with 3-year follow-up without pulmonary, renal or other forms of lymphatic involvement.

Downloads

Download data is not yet available.

References

Matsui K, Tatsuguchi A, Valencia J, Yu Zx, Bechtle J, Beasley MB, et al. Extrapulmonary lymphangioleiomyomatosis (LAM): clinicopathologic features in 22 cases. Hum Pathol. 2000;31:1242. doi: 10.1053/hupa.2000.18500.

Schoolmeester JK, Park KJ. Incidental Nodal Lymphangioleiomyomatosis Is Not a Harbinger of Pulmonary Lymphangioleiomyomatosis: A Study of 19 Cases with Evaluation of Diagnostic Immunohistochemistry. Am J Surg Pathol. 2015;39:1404-10. doi: 10.1097/PAS.0000000000000470.

Tobino K, Johkoh T, Fujimoto K, Sakai F, Arakawa H, Kurihara M, et al. Computed tomographic features of lymphangioleiomyomatosis: evaluation in 138 patients. Eur J Radiol. 2015 Mar;84(3):534-41. doi: 10.1016/j.ejrad.2014.12.008.

Urban T, Lazor R, Lacronique J, Murris M, Labrune S, Valeyre D, et al. Pulmonary lymphangioleiomyomatosis. A study of 69 patients. Groupe d'Etudes et de Recherche sur les Maladies "Orphelines" Pulmonaires (GERM"O"P). Medicine. 1999;78:32137. DOI: 10.1097/00005792-199909000-00004.

Johnson SR, Cordier JF, Lazor R, Cottin V, Costabel U, Harari S, et al. European Respiratory Society guidelines for the diagnosis and management of lymphangioleiomyomatosis. Eur Respir J. 2010; 35: 14-26. doi: 10.1183/09031936.00076209.

Grzegorek I, Drozdz K, Podhorska-Okolow M, Szuba A, Dziegiel P, et al. LAM cells: biology and Lymphangioleiomyomatosis. Folia Histochem Cytobiol. 2013; 51: 1-10. doi: 10.5603/FHC.2013.001.

McCormack FX, Gupta N, Finlay GR, Young LR, Taveira-DaSilva AM, Glasgow CG, et al. Official American Thoracic Society/Japanese Respiratory Society Clinical Practice Guidelines: Lymphangioleiomyomatosis Diagnosis and Management. Am J Respir Crit Care Med. 2016;194:748–61. doi: 10.1164/rccm.201607-1384ST.

Wahid S, Chiang PC, Lun Luo H, Huan SC, Tsai EM, Chiang PH. Pelvic lymphangioleiomyomatosis treated successfully with everolimus - Two case reports with literature review. Medicine. 2017; 96: e4562.doi: 10.1097/MD.0000000000004562.

Freitas C, Baldi B, Araújo M, Heiden GI, Kairalla RA, Carvalho CR. Use of sirolimus in the treatment of lymphangioleiomyomatosis: favorable responses in patients with different extrapulmonary manifestations. J. Bras Pneumol. 2015;41:275-80. Doi: 10.1590/S1806-37132015000004553.

Cai Y, Guo H, Wang W, Li H, Sun H, Shi B, et al. Assessing the outcomes of everolimus on renal angiomyolipoma associated with tuberous sclerosis complex in China: a two years trial. Orphanet J Rare Dis. 2018;13:43. doi: 10.1186/s13023-018-0781-y.

Schiavina M, Contini P, Fabiani A, Cinelli F, Di Scioscio V, Zompatori M, et al. Efficacy of hormonal manipulation in lymphangioleiomyomatosis. A 20-year-experience in 36 patients. Sarcoidosis Vasc Diffuse Lung Dis. 2007;24:39-50.

Taveira-DaSilva AM, Moss J. Management of lymphangioleiomyomatosis. F1000Prime Rep. 2014;6:116. doi: 10.12703/P6-116.

Johnson SR, Tattersfield AE. Decline in lung function in lymphangioleiomyomatosis: relation to menopause and progesterone treatment. Am J Respir Crit Care Med. 1999;160:628–33. doi: 10.1164/ajrccm.160.2.9901027.

Gupta N, Lee HS, Young LR, Strange C, Moss J, Singer LG, et al. Analysis of the MILES cohort reveals determinants of disease progression and treatment response in lymphangioleiomyomatosis. Eur Respir J. 2019;53:1802066. doi: 10.1183/13993003.02066-2018.

Downloads

Published

2021-09-23

How to Cite

1.
Soeiro B, Correia-Pinto J, Vasconcelos A, Salgado M. Isolated Nodal Retroperitoneal Sporadic Lymphangioleiomyomatosis. RPMI [Internet]. 2021 Sep. 23 [cited 2024 Nov. 21];27(4):320-3. Available from: https://revista.spmi.pt/index.php/rpmi/article/view/102

Most read articles by the same author(s)